



Department of Pesticide Regulation



Mary-Ann Warmerdam
Director

Arnold Schwarzenegger
Governor

July 16, 2009

TO: Pesticide Registration and Evaluation Committee

SUBJECT: PRIORITIZATION AND STATUS OF ACTIVE INGREDIENTS FOR RISK CHARACTERIZATION: REPORT 51

The Birth Defect Prevention Act of 1984 (SB 950) requires the California Department of Pesticide Regulation (DPR) to review the toxicology data for all active ingredients currently registered in California.

As part of this review, the active ingredients listed on the attached list were identified as having potential adverse health effects in studies of sufficient quality to permit risk characterization. As a result, these active ingredients will enter the risk characterization process. During this process, DPR staff will identify the seriousness of the adverse effect, determine the expected levels of human exposure, assess the resulting risk to human health, and, if necessary, explore possible mitigation measures.

The results of this risk characterization process will help DPR staff determine if any registration action is warranted. A registration action is not the automatic result for every active ingredient entering the risk characterization process. In addition, as data gaps are filled, other adverse effects might be identified, necessitating another risk characterization. Finally, the risk characterization process should be viewed as a comprehensive evaluation requiring, in some cases, a considerable amount of time. Therefore, it is not possible to predict how long it will take to systematically complete the risk characterization process for each priority category.

The risk characterization document is forwarded to the Assistant Director for approval. When the risk characterization process has been completed, the active ingredient will be removed from this list. Any subsequent risk management activities will be conducted under a separate DPR process.

Attached is a list of active ingredients and the type of corresponding study in which the potential adverse health effects were noted. The active ingredients have been prioritized into High, Moderate, and Low categories.



Pesticide Registration Evaluation Committee
July 16, 2009
Page 2

The prioritization of the active ingredients is a subjective process based upon the nature of potential adverse effect, the number of potential adverse effects, the number of species affected, the no observable effect level (NOEL), potential human exposure, use patterns, quantity used, EPA evaluations and actions, etc. In addition, the status of the active ingredients in risk characterization under Senate Bill 950 (Birth Defects Prevention Act), Assembly Bill (AB) 1807 (Toxic Air Contaminant Act), AB 2161 (Food Safety Act), Proposition 65, and new registration submissions are provided in this report.

Questions about the information contained in this report can be directed to Dr. Joyce Gee, Senior Toxicologist in the Medical Toxicology Branch, at 916-324-3465, or by e-mail at <jgee@cdpr.ca.gov>.

Sincerely,

Gary Patterson, Ph.D., Chief
Medical Toxicology Branch
916-324-3466

Attachment

cc: Dr. Joyce Gee, Senior Toxicologist

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

The following is a list of the active ingredients that will undergo or are undergoing a risk assessment. The active ingredients have been prioritized into High, Moderate and Low categories. Also listed is the type of toxicity study in which the possible adverse effect(s) was noted.

<u>Active Ingredient</u>	<u>Studies Indicating Possible Adverse Effects</u>
High Priority	
1. Acephate	Genotoxicity study, oncogenicity study, chronic toxicity study, low NOEL
2. Acrolein	Genotoxicity study, chronic toxicity study, oncogenicity study, reproduction study
3. Aldicarb	Low NOEL
4. Arsenic, inorganic	Oncogenicity study (epidemiology), neurotoxicity (epidemiology), genotoxicity study, teratology study
5. Azafenidin	Chronic toxicity study, oncogenicity study, teratology study, reproduction study
6. Bromoxynil	Genotoxicity study, oncogenicity study, teratology study
7. Captan	Genotoxicity study, oncogenicity study
8. Carbaryl	Genotoxicity study, oncogenicity study
9. Chloropicrin	Genotoxicity study, teratology study
10. Chlorothalonil	Combined oncogenicity/chronic toxicity study, oncogenicity study, genotoxicity study
11. Chlorpyrifos	Genotoxicity study, reproduction study
12. Cyfluthrin	Teratology study, reproduction study
13. λ -Cyhalothrin (lambda form)	Chronic toxicity study, oncogenicity study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

14.	2,4-D	Combined oncogenicity/chronic toxicity study, reproduction study, genotoxicity study
15.	Daminozide	Oncogenicity study
16.	Dazomet	Chronic toxicity study, teratology study, genotoxicity study
17.	Diazinon	Genotoxicity study, reproduction study
18.	Dicamba	Neurotoxicity study, chronic toxicity study, oncogenicity study
19.	Dichlobenil	Combined oncogenicity/chronic toxicity study
20.	1,3-Dichloropropene (Telone)	Systemic toxicity/short term exposure
21.	Dicofol	Oncogenicity study, low NOEL, reproduction study
22.	Dimethoate	Genotoxicity study, low NOEL
23.	Disulfoton	Genotoxicity, low NOELs
24.	Emamectin Benzoate	Neurotoxicity in subchronic and chronic studies, reproduction study
25.	Ethylene oxide	Combined oncogenicity/chronic toxicity study, oncogenicity study, genotoxicity study
26.	Ethylene thiourea (ETU)	Genotoxicity study, chronic toxicity study, combined oncogenicity/chronic toxicity study
27.	Famoxadone	Chronic toxicity study; genotoxicity study
28.	Fenamiphos	Genotoxicity study, low NOEL
29.	Fenbuconazole	Chronic toxicity study, oncogenicity study, combined oncogenicity/chronic toxicity study, reproduction study, teratology study
30.	Fenvalerate/Esfenvalerate	Neurotoxicity

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

31.	Fipronil	Chronic toxicity study, combined chronic toxicity/oncogenicity study
32.	Flonicamid	Oncogenicity
33.	Flumioxazin	Chronic toxicity study, reproduction study, teratology study
34.	Glufosinate ammonium	Chronic toxicity study, teratology study
35.	Glutaraldehyde	Genotoxicity study, subchronic toxicity study, combined toxicity study
36.	Imazalil	Teratology study
37.	Indoxacarb	Subchronic toxicity studies, combined chronic toxicity/oncogenicity study, chronic toxicity study, oncogenicity study, neurotoxicity study
38.	Iprodione	Genotoxicity study, chronic toxicity studies, oncogenicity study
39.	Linuron	Combined oncogenicity/chronic toxicity study, oncogenicity study, chronic toxicity study, reproduction study
40.	Mancozeb	Genotoxicity study, chronic toxicity study (also see ETU)
41.	Methiocarb	Teratology study
42.	Methyl parathion	Reproduction study, teratology study, genotoxicity study, chronic toxicity study
43.	Metofluthrin	Oncogenicity, neurotoxicity
44.	Milbemectin	Reproduction study, neurotoxicity study, subchronic toxicity study
45.	N-octylbicycloheptene dicarbomixide (MGK-264)	Oncogenicity study
46.	Novaluron	Chronic toxicity

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

47.	Orthophenylphenol	Genotoxicity study, oncogenicity study, teratology study
48.	Oxadiazon	Chronic toxicity study, oncogenicity study, genotoxicity study, teratology study
49.	Oxydemeton-methyl	Reproduction study, genotoxicity study
50.	Paradichlorobenzene	Oncogenicity study, reproduction study, genotoxicity study
51.	Paraquat dichloride	Genotoxicity study, oncogenicity study, combined oncogenicity/chronic toxicity study, chronic toxicity study
52.	PCNB	Genotoxicity study, oncogenicity studies
53.	Profenofos	Low NOEL, chronic toxicity study
54.	Propanil	Combined oncogenicity/chronic toxicity study, chronic toxicity study, oncogenicity study
55.	Propargite	Reproduction study, genotoxicity study, combined oncogenicity/chronic toxicity study
56.	Propylene oxide	Genotoxicity study, oncogenicity study
57.	Propyzamide	Oncogenicity study
58.	Pyraclostrobin	Subchronic toxicity study, low NOEL's in teratology , chronic and reproduction studies
59.	Sodium tertathiocarbonate (CS ₂)	Multiple toxicity studies
60.	Spirodiclofen	Chronic dog, rat and mouse oncogenicity, Rat reproduction
61.	Spiromesifin	Low NOELs
62.	Spirotetramat	Chronic and oncogenicity
63.	Sulfentrazone	Chronic rat, reproductive effects, rat Developmental toxicity
64.	Tebuconazole	Teratology study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

65.	Thiacloprid	Oncogenicity, reproductive toxicity
66.	<i>Thiamethoxam*</i>	Oncogenicity, chronic toxicity
67.	Thiazopyr	Subchronic toxicity study, combined oncogenicity /chronic toxicity study
68.	Thiophanate-methyl	Oncogenicity studies, chronic toxicity studies
69.	Tralkoxydim	Chronic toxicity study, combined toxicity study, teratology study
70.	Triadimefon	Teratology study, oncogenicity study, reproduction study, chronic toxicity study
71.	Triallate	Oncogenicity study, chronic toxicity study, genotoxicity study
72.	Tributyltin benzoate	Developmental toxicity study, oncogenicity study
73.	Trifloxysulfuron-sodium	Neurotoxicity study
74.	Vinclozolin	Chronic toxicity study, teratology study, genotoxicity study, reproduction study
75.	Ziram	Oncogenicity study, reproduction study, genotoxicity study

Moderate Priority

1.	Acequinocyl	Chronic toxicity study, reproduction study
2.	Acetamiprid	Subchronic and chronic toxicity studies
3.	Acibenzolar-s-methyl	Combined chronic toxicity/oncogenicity study, teratology study, genotoxicity study, chronic toxicity study, subchronic toxicity study
4.	Alkyldimethyl benzyl ammonium chloride	Teratology study
5.	Azoxystrobin	Teratology study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

6.	Bensulide	Chronic toxicity study, low NOEL, delayed neurotoxicity study
7.	Bentazon, sodium salt	Teratology study, oncogenicity study
8.	Bifenazate	Chronic toxicity study, combined toxicity study
9.	Boric acid	Chronic toxicity study, teratology study
10.	Boscalid (BAS510F)	Oncogenicity study
11.	Bromacil	Oncogenicity study, genotoxicity study
12.	Buprofezin	Subchronic toxicity study, chronic toxicity study, combined toxicity study, teratology study
13.	Cacodylic acid	Genotoxicity study, chronic toxicity study, oncogenicity study, teratology study
14.	Carboxin	Genotoxicity study, oncogenicity study, chronic toxicity study
15.	Chlorflurenol, methyl ester	Chronic toxicity study, teratology study
16.	Chlorthal-dimethyl	Combined oncogenicity/chronic toxicity study, oncogenicity study
17.	Clomazone	Chronic toxicity study, teratology study
18.	Clothianidin	Genotoxicity, neurotoxicity (subchronic study)
19.	<i>Coumaphos*</i>	<i>Cholinesterase inhibition, neurotoxicity</i>
20.	Cryolite	Oncogenicity study
21.	Cyanuric acid, monosodium salt	Combined oncogenicity/chronic toxicity study
22.	Cyclanilide	Combined oncogenicity/chronic toxicity study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

23.	Cymoxanil	Genotoxicity study, chronic toxicity study, teratology study
24.	Cypermethrin	Chronic toxicity studies, oncogenicity study, reproduction study
25.	Cyphenothrin	Neurotoxicity
26.	Cyprodinil	Subchronic toxicity study, combined oncogenicity/chronic toxicity study
27.	2,4-DB [4-(2,4-dichlorophenoxy)butyric acid]	Genotoxicity studies, reproduction study
28.	<i>2,2-Dibromo-3-nitrilopropionamide</i>	<i>Developmental study</i>
29.	Dichloran/Dicloran	Genotoxicity study, chronic toxicity study, reproduction study
30.	Didecyldimethyl-ammonium chloride	Low NOEL
31.	N,N-Diethyl-2-(4-methylbenzyloxy)-ethylamine Hydrochloride (PT807-HCL)	Subchronic toxicity study, chronic toxicity studies
32.	Difenacoum	Genotoxicity, chronic effects
33.	Difenoconazole	Teratology studies, combined oncogenicity/chronic toxicity study
34.	Difethialone	Low NOEL (acute, subchronic)
35.	Dimethenamid-P	Rat oncogenicity/chronic toxicity, low NOEL
36.	Dimethomorph	Oncogenicity study, chronic toxicity study, genotoxicity study
37.	O,O-Dimethyl O-(4-nitro-M-tolyl)-phosphorothioate (Sumithion)	Low NOEL (subchronic study), oncogenicity study, reproduction study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

38.	Dinotefuran	Reproduction study, chronic toxicity study, subchronic toxicity study
39.	Diphenylamine	ombined chronic toxicity/oncogenicity study
40.	Dipropyl iso-cinchomeronate (MGK-326)	Oncogenicity studies
41.	Dithiopyr	Subchronic toxicity studies
42.	Diuron	Genotoxicity study, oncogenicity studies
43.	Dodine	Oncogenicity study
44.	Endothall	Chronic toxicity study, oncogenicity study
45.	Esbiothrin	Genotoxicity study, reproduction study
46.	Ethalfuralin	Chronic toxicity study, genotoxicity study, combined oncogenicity/chronic toxicity study
47.	Ethofumesate	Teratology study
48.	Etoxazole	Genotoxicity study
49.	Fenarimol	Combined oncogenicity/chronic toxicity study
50.	Flubendiamide	Chronic effects in multiple studies
51	Fludioxonil	Combined oncogenicity/chronic toxicity study, subchronic toxicity study
52.	Fluopicolide	Oncogenicity and liver changes
53.	Fluoxastrobin	Oncogenicity
54.	Fluroxypyr	Chronic toxicity study, subchronic toxicity study
55.	Flurprimidol	Chronic toxicity study, teratology study, reproduction study
56.	τ -Fluvalinate (tau form)	Genotoxicity study, reproduction study, teratology study, chronic toxicity study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

57.	Forchlorfenuron	Genotoxicity study
58.	Formaldehyde	Genotoxicity study, oncogenicity study
59.	Halosulfuron	Chronic toxicity study
60.	Hexahydro-1,3,5-triethyl-S-triazine	Teratology study
61.	Hexythiazox	Oncogenicity study
62.	(Hydroxymethyl)phosphonium sulfate (Tetrakis)	Teratology study
63.	Imidacloprid	Combined oncogenicity/chronic toxicity study, teratology study, genotoxicity study
64.	Imiprothrin	Teratology study, neurotoxicity study, chronic toxicity study, genotoxicity study
65.	<i>Ipconazole*</i>	<i>No specific effect; reduced body weight in several species</i>
66.	Isoxaben	Oncogenicity studies, genotoxicity study.
67.	Kresoxim-methyl	Combined chronic toxicity/oncogenicity study
68.	<i>Mandipropamid*</i>	<i>Organ and body weight effects</i>
69.	MCPA	Genotoxicity study
70.	Mecoprop (MCP)	Oncogenicity study, genotoxicity study
71.	Mefenoxam	Genotoxicity study
72.	Mefluidide, diethanolamine salt	Combined oncogenicity/chronic toxicity study, oncogenicity study, chronic toxicity study
73.	Metaflumizone	Genotoxicity
74.	Metalaxyl	Genotoxicity study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

75.	Methomyl	Oncogenicity study, chronic toxicity study
76.	Methoxyfenozide	Chronic toxicity study, combined toxicity study, reproduction study
77.	Metribuzin	Chronic toxicity study
78.	MSMA/MAA	Combined oncogenicity/chronic toxicity study
79.	Napropamide	Combined oncogenicity/chronic toxicity study, genotoxicity study
80.	Napthalene acetic acid	Reproduction study, teratology study, chronic toxicity study, combined toxicity study
81.	Norflurazon	Chronic toxicity study
82.	Noviflumuron (XDE-007)	Reproduction study
83.	Ortho-benzyl-para-chlorophenol	Teratology study
84.	Oryzalin	Oncogenicity study, chronic toxicity study
85.	Oxyfluorfen	Genotoxicity study, oncogenicity study, teratology study
86.	Oxythioquinox	Chronic toxicity study, reproduction study, teratology study, genotoxicity study
87.	Pebulate	Combined oncogenicity/chronic toxicity study, chronic toxicity study
88.	Penoxsulam	Oncogenicity
89.	Permethrin	Reproduction study, chronic toxicity study, oncogenicity study
90.	Phenol	Oncogenicity studies
91.	Phenothrin	Oncogenicity study, reproduction toxicity study
92.	Phorate	Low NOEL

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

111.	<i>Saflufenacil*</i>	Genotoxicity (also, anemia)
112.	Simazine	Combined oncogenicity/chronic toxicity study
113.	Spinetoram	Chronic toxicity
114.	Spinosad	Chronic toxicity study, combined chronic toxicity/oncogenicity study
115.	Sulfosulfuron	Chronic toxicity, oncogenicity
116.	TCMTB	Oncogenicity study
117.	Tebufenozide	Chronic toxicity studies
118.	Terbuthylazine (Bellacide)	Low NOEL
119.	Tetrachlorvinphos	Oncogenicity study, genotoxicity study
120.	Tetraconazole	Oncogenicity (sugarbeets only use)
121.	Thiamethoxam	Combined chronic toxicity/oncogenicity study, chronic toxicity study, oncogenicity study
122.	Thiodicarb	Oncogenicity study, reproduction study, genotoxicity study
123.	Thiram	Low NOEL, teratology study, chronic toxicity study, combined oncogenicity/chronic toxicity study
124.	<i>Tribenuron-methyl*</i>	<i>Reproduction study</i>
125.	Trichlorfon	Combined chronic toxicity/oncogenicity study, genotoxicity study
126.	Triclopyr	Genotoxicity study, low NOEL
127.	Trifloxystrobin	Oncogenicity study, chronic toxicity study, genotoxicity study
128..	Triflumizole	Chronic toxicity study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

129.	Trifluralin	Combined oncogenicity/chronic toxicity study, oncogenicity study
130.	Triforine	Teratology study, oncogenicity study
131.	Tris (hydroxymethyl nitromethane)	Genotoxicity study, teratology study
132.	Trisulfuron-methyl	Chronic toxicity study, oncogenicity study
133.	<i>Triticonazole*</i>	<i>Chronic dog (eye effects); genotoxicity</i>
134.	Uniconazole-P	Chronic toxicity study, oncogenicity study, genotoxicity study, low NOEL
135.	Zinc 2-Pyridinethiol-1-oxide (<i>omadine</i>)	Teratology studies

Low Priority

1.	Alachlor	Oncogenicity study, chronic toxicity study, low NOEL
2.	Alpha-isoctadecyl-omega-hydroxy-poly(oxyethylene)	None identified
3.	Aminopyralid	Chromosome aberrations
4.	4-t-Amylphenol (Para-tert-amylphenol)	None identified
5.	Azadirachten	None identified
6.	Bacillus subtilis	None identified
7.	Bacillus thuringiensis	None identified
8.	Beauveria bassiana	None identified
9.	Benefin	Combined chronic toxicity/oncogenicity study
10.	Benzyl benzoate	None identified

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

11.	Bronopol	Chronic toxicity study, low NOEL
12.	Butylate	Genotoxicity study, neurotoxicity study
13.	N-Butyl-1,2-benzisothiazole-3-one	Genotoxicity
14.	Carfentrazone-ethyl	Chronic toxicity studies
15.	Chlorhexidine diacetate	Dermal (local) effects
16.	1-(3-Chloroallyl)-3,5,7-triazazoniaadamantane	Genotoxicity study, teratology study
17.	4-Chloro-3,5-xyleneol	Genotoxicity study
18.	Chlorpropham	Genotoxicity study
19.	Chlorsulfuron	Chronic toxicity study
20.	Clethodim	Genotoxicity study
21.	Clopyralid	Subchronic toxicity study; combined oncogenicity/chronic toxicity study
22.	<i>Copper 2-pyridinethiol-oxide (Omadine)*</i>	<i>Neurotoxicity</i>
23.	Cyazofamid	Body and organ weight effects
24.	N-Cyclopropyl-N'-(1,1-dimethylethyl)-6-(methylthio)-1,3,5-triazine-2,4-diamine (Irgarol)	None identified
25.	2,4-DP	Combined oncogenicity/chronic toxicity study
26.	Desmedipham	Genotoxicity study, teratology study
27.	1,2-Dibromo-2,4-dicyanobutane (Tektamer 38)	Subchronic toxicity study
28.	4,5-Dichloro-2-noctyl-3(2H)-isothiazolone (Sea-Nine)	Antimicrobial; local corrosive effects

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

29.	Dichlorprop-p	Chronic toxicity studies
30.	Difenzoquat methyl sulfate	Chronic toxicity study
31.	Diflufenzopyr	Teratology study, reproduction study
32.	Dimethipin	Chronic toxicity study
33.	Dimethoxane	Oncogenicity study, genotoxicity study
34.	5,5-Dimethylhydantoin	Chronic toxicity studies
35.	4,4-Dimethyloxazolidine	Genotoxicity study
36.	Ethephon	Genotoxicity study
37.	Fenamidone	Chronic toxicity studies, genotoxicity studies
38.	Fenhexamid	Subchronic and chronic toxicity studies
39.	Flumiclorac-pentyl	Chromosome aberrations
40.	Fluridone	Chronic toxicity study, oncogenicity study
41.	Flutolonil	Genotoxicity study, combined oncogenicity/chronic toxicity study
42.	Foramsulfuron	Genotoxicity study
43.	Formetanate hydrochloride	Genotoxicity study
44.	Fosetyl-Al	Combined oncogenicity/chronic toxicity study
45.	Gliocladium verens	None identified
46.	Glyphosate	Oncogenicity studies
47.	Halofenozide	Teratology study, subchronic toxicity study
48.	Hexazinone	Genotoxicity study
49.	Hydroprene	Chronic toxicity study, oncogenicity study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

50.	5-Hydroxymethyl-1-aza-3,7-dioxabicyclo-(3,3,0)octane	Genotoxicity study
51.	Imazamethabenz	Subchronic toxicity study, combine chronic toxicity/oncogenicity study
52.	Imazamox	Teratology studies
53.	Imazapic	Chronic toxicity study
54.	Imazapyr	Teratology study
55.	Imazethapyr	Genotoxicity study, teratology study
56.	Intersept (for chemical details, see chemicals 3836, 3837, 3838)	Teratology study
57.	Maleic hydrazide	Genotoxicity study
58.	Maneb (also see ETU-High Priority)	Genotoxicity study
59.	Mepiquat chloride	Chronic toxicity studies
60.	Mesosulfuron-methyl	Subchronic toxicity study
61.	Metaldehyde	Chronic toxicity study
62.	Methylene bis(thiocyanate)	Genotoxicity study
63.	Metolachlor	Oncogenicity study, chronic toxicity study
64.	Nicosulfuron (Accent)	None identified
65.	Nithiazine	Neurotoxicity study
66.	Nitrapyrin	Combined oncogenicity/chronic toxicity study
67.	4-(2-Nitrobutyl) morpholine/ 4,4'-(2-ethyl-2-nitrotrimethylene) morpholine	Genotoxicity study
68.	Octhilinone	Genotoxicity study
69.	Orthosulfamuron	Oncogenicity and chronic liver changes

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

70.	Oxamyl	Chronic toxicity study
71.	Oxazolidine E (Bioban)	Teratology study
72.	Parachlorometacresol	Antimicrobial; local irritant
73.	Pendimethalin	Oncogenicity study
74.	Phenmedipham	None identified; incomplete data base
75.	Piperonyl butoxide	Oncogenicity study
76.	Prodiamine	Teratology study, genotoxicity study
77.	Prohexadione calcium	Chronic toxicity study, genotoxicity study
78.	Prometryn	None identified
79.	Propoxycarbazone-sodium	None identified
80.	Pseudomonas cepacia (Blue Circle)	None identified
81.	Pseudomonas fluorescens (Frostban A&B)	None identified
82.	Pseudomonas syringae	None identified
83.	Pyrazon	Chronic toxicity studies
84.	Rotenone	Genotoxicity study
85.	Sethoxydim	Teratology study, chronic toxicity study
86.	Siduron	Oncogenicity study
87.	Sodium hydroxymethyl glycinate	None identified
88.	Streptomyces griseoviridis (Mycostop)	None identified
89.	Tebuthiuron	Reproduction study, teratology study, mutagenicity study
90.	Tetramethrin	Reproduction study, oncogenicity study, teratology study

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

- | | | |
|-----|--------------------------------|--|
| 91. | Thiobencarb | Genotoxicity study |
| 92. | <i>Tralopyril*</i> | Antifouling paint |
| 93. | Trinexapac-ethyl (Cimectacarb) | Combined oncogenicity/chronic toxicity study |

CHANGES TO THE RISK ASSESSMENT PRIORITIZATION LIST

A. Changes in Status of Active Ingredients Already on Prioritization List

B. Active Ingredients Removed from Prioritization List ^a (1)

Endosulfan

C. Active Ingredients Added to Prioritization List (11)

*Copper 2-pyridinethiol-oxide (Omadine)**

*Coumaphos**

*2,2-Dibromo=3=nitrilopropionamide**

*Ipconazole**

*Mandipropamid**

*Pinoxaden**

*Saflufenacil**

*Thiamthoxam**

*Tralopyril**

*Tribenuron-methyl**

*Triticonazole**

a/ A completed risk assessment must be approved by Assistant Director before it can be removed from the PREC prioritization list

STATUS OF ACTIVE INGREDIENTS CURRENTLY IN RISK ASSESSMENT

Note: The following list only includes those active ingredients that are currently in risk assessment. It does not include the active ingredients in risk mitigation/risk management. Once the risk assessment for a specific active ingredient has been completed and approved by the Assistant Director, that active ingredient is removed from the SB-950/PREC Prioritization List. In addition to conducting a risk assessment under SB-950 for occupational and residential exposures, many risk assessments contain a dietary component under AB-2161 and an air component under AB-1807. Whenever possible, these components are included in one, comprehensive risk characterization document.

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

The following stages of the risk assessment process are included in this status section:

Hazard Identification Stage: includes the development of the Toxicology Profile Section and the selection of the definitive studies, critical endpoints and NOEL/LOEL/oncogenicity potency values that will be used for risk characterization. Responsibility: Medical Toxicology Branch.

Exposure Assessment Stage: includes the development of occupational, residential, dietary (food/water), ambient air and off-site air exposure scenarios. Responsibility: Worker Health and Safety Branch for occupational, residential and air. Medical Toxicology Branch for dietary.

Risk Characterization Stage: includes the development of quantitative values used to assess the risk from critical NOELs/oncogenic potency factors and exposure values. Responsibility: Medical Toxicology Branch

Review Stage: includes the review of the final draft of the Risk Characterization Document within DRP and externally by OEHHA, US EPA and other interested parties. Also includes development of DPR response to reviewers comments.

Approval Stage: completed Risk Characterization Document awaiting approval by Assistant Director.

DDVP Addendum 3

Inactive : No current risk assessment activities because of higher priorities.

- . Paraquat-- Hazard identification stage - inactive
- Propyzamide - Inactive

Active Ingredients

1. *Acephate –Response stage (OEHHA, US EPA)*
2. Acrolein – Hazard identification stage
3. *Carbaryl – Response stage (OEHHA, US EPA)*
4. *Chloropicrin – Review stage (OEHHA, US EPA) (PREC presentation)*
5. *Chlorothalonil – Review stage (occupational/air)(OEHHA, US EPA)*
6. Chlorpyrifos – response stage (occupational/air)(OEHHA US EPA)
7. Cyfluthrin – Hazard identification phase
8. Diazinon – Hazard identification phase

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 51

July 16, 2009

9. 1,3-dichloropropene (Telone) – Risk characterization phase (acute, air)
10. Dicofol – Hazard identification phase
11. Esfenvalerate – Hazard identification stage
12. Fipronil - Hazard identification and exposure assessment stages
13. Indoxacarb– Hazard identification and exposure assessment stages
14. Methomyl – Hazard identification stage (dietary)
15. *Methyl iodide- Review stage (OEHHA, US EPA)*
16. Methyl parathion – Risk characterization stage (occupational)
17. Paradichlorobenzene – Hazard identification stage
18. Phosphine – Hazard identification and exposure assessment stages
19. Propargite – Risk characterization stage (occupational)
20. Simazine - Hazard identification and exposure assessment stages
21. Sodium tetrathiocarbonate - Hazard identification and exposure assessment stages

Changes from previous Report #50 (3/2008) are in italics

* new active ingredient